Patient recruitment is a critical bottleneck in global clinical research. Despite advances in medicine, finding and enrolling the right participants on time remains one of the biggest causes of trial delays. Studies show that 80–85% of clinical trials fail to meet their enrollment targets, and nearly 30% of research sites recruit no patients at all.
This chronic under-recruitment prolongs drug development, raises costs, and can compromise the generalizability of study results. In a competitive landscape with hundreds of thousands of trials ongoing worldwide, sponsors, CROs, investigators and data managers must adopt smarter strategies. Both the European Medicines Agency (EMA) and the U.S. FDA emphasize patient-centric trial designs and innovative methods to improve recruitment and diversity.
Global regulatory context and trends
In recent years, regulatory agencies have pushed for broader patient access to trials. The EU Clinical Trial Regulation (No. 536/2014) introduced a centralized application portal (CTIS) and requires transparency of trial data, aiming to streamline multinational studies across Europe.
Likewise, the FDA encourages inclusion of diverse populations and patient engagement, issuing guidance on e.g. decentralized elements and use of digital health in trials. Both regions see recruitment as integral to trial quality: for instance, EMA’s December 2021 publications underscore patient-centricity and FDA initiatives on diversity (though evolving) reflect a demand for reaching underrepresented groups.
This global push comes amid new challenges: patient expectations are rising post-pandemic, and trials increasingly target narrow subgroups (e.g. genetic biomarkers) or rare diseases. Consequently, more trials require recruiting hard-to-find patients. At the same time, technology has evolved: cloud databases, telemedicine, e-consent platforms, and AI-driven analytics now offer new tools.
Many sponsors report that COVID-19 spurred adoption of decentralized trial (DCT) models, which in turn can expand recruitment by eliminating geographical barriers. EMA’s recent recommendations on DCT elements highlight that patient safety must remain paramount even when visits are remote, indicating regulators’ cautious support of such innovations.
Key challenges in patient enrollment
Several obstacles hinder patient recruitment globally:
- Strict eligibility criteria: Highly selective inclusion/exclusion criteria (for safety or scientific reasons) often reduce the pool of eligible patients, especially in oncology and rare disease studies.
- Lack of awareness: Most potential participants are unaware of relevant trials. Surveys show that while 64% of people think they should learn about clinical research from their doctors, only 0.2% actually get recruited via physicians . This gap means that traditional referral networks and general practitioners may not be fully utilized to inform patients.
- Trial burden and travel: Frequent hospital visits, long procedures, or complex protocols can deter participants. In decentralized or hybrid trials, these burdens are reduced, but many sites still rely on conventional in-person models.
- Diversity and inclusion: Historically, trials have under-enrolled certain demographic groups (women, ethnic minorities, the elderly). Regulators now expect sponsors to proactively plan for diversity. Data from WCG show that industry efforts have helped increase minority representation by ~25% and female participation to 52% in recent years . Nonetheless, achieving true inclusivity often requires targeted outreach and possibly trial design adjustments.
As Clinical Leader reports, even before the pandemic most trials already struggled with enrollment: “the single largest cause of trial delays” has been patient recruitment, with many trials not hitting initial enrollment targets . The cost of delays is substantial: late enrollment can add months to development timelines and millions to budgets.
Technological and strategic solutions
To overcome these hurdles, sponsors and CROs are leveraging new strategies:
- Digital recruitment and data analytics: Advanced search platforms and AI matching tools scan electronic health records (EHRs), registries and claims data to flag eligible patients much faster than manual methods. Digital advertising via patient portals and social media campaigns allows precise targeting (for example, rare disease patient communities). Integrated Clinical Trial Management Systems (CTMS) can coordinate these efforts in real time.
- Decentralized trial models: By moving some trial procedures to patients’ homes (telemedicine visits, mobile nursing, home delivery of investigational drugs), trials become accessible to participants far from specialized centers. EMA’s new guideline clarifies how remote elements fit within EU law . In the U.S., FDA’s guidance encourages “fit-for-purpose” use of digital tools to collect data while protecting privacy. Practical examples include wearable sensors for remote monitoring, eConsent on tablets, and telehealth visits to reduce in-person burden. These methods can widen the geographic catchment of trials and improve retention by making studies more patient-friendly.
- Patient engagement and retention: The focus is shifting to design trials around participants, not just disease pathology. Flex Databases notes that “in 2025, patient engagement is a measurable part of trial success” . Mobile apps, interactive portals, and regular communication keep participants informed and motivated. Including patient representatives in protocol design can identify and eliminate unnecessary hurdles. Creating clear plans for patient retention (e.g. schedules of reminders, community support) also combats drop-out.
- Global collaboration: International partnerships and multi-site networks enable broader recruitment. For example, large oncology trials often involve sites across Europe, North America and Asia to reach enough patients. Regulatory harmonization efforts (like ICH E17 on multi- regional trials) facilitate this. Some sponsors also use global patient advocacy groups to spread awareness of trials.
- Focus on diversity: Global sponsors are now required (or strongly recommended) to meet diversity targets. Learning from initiatives (e.g. NIH’s U.S. initiatives on diversity in trials), companies use multilingual consent forms, culturally sensitive outreach, and flexible site locations (including community clinics). As a result, data from 2018–2022 indicate significant gains: minority enrollment up 25%, women’s participation over 50% . Trials that incorporate inclusive design report higher retention among diverse groups.
Overall, the integration of technology with patient-centered strategies is key. The combination of AI- driven recruitment tools, decentralized elements, and active patient engagement forms a “precision recruitment” approach. This aligns with industry analyses predicting that future successful trials will be those that treat recruitment as a core part of trial design, not an afterthought .
Worldwide, patient recruitment remains a critical challenge but also a major opportunity for innovation. By embracing regulatory guidance (EMA and FDA both prioritize patient-centric designs), leveraging technology (AI, e-consent, telemedicine) and focusing on inclusivity, sponsors and investigators can dramatically improve enrollment and retention. This not only speeds up trials but also ensures broader representation and higher-quality data.
Our company specializes in clinical trial management solutions that support advanced recruitment strategies. We provide integrated platforms for digital patient matching, e-trial tools, and analytics that help target the right patients efficiently.
Contact us to learn how our technologies and services can enhance your patient recruitment efforts and accelerate your clinical study’s success.